• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Press release

Phase Holographic: PHI IS OPENING A NEW DEVELOPMENT OFFICE IN THE US

As a result of the newly created alliance for advancing cell-based biomanufacturing (https://phiab.com/pressrelease/phi-sas-qiagen-and-biospherix-form-alliance-to-advance-cell-based-biomanufacturing/) which was recently communicated, Phase Holographic Imaging (PHI) is taking the next step in its investment into regenerative medicine by opening an office in the Innovation Quarter (https://www.innovationquarter.com/) in Winston-Salem.

The new office is in, what is called, the Regenerative Medicine Hub (RegenMed Hub™), where PHI will develop its non-invasive technology for cell quality control in the field of regenerative medicine. With this step, PHI will have access to Wake Forest Institute facilities and expertise to test and develop its non-invasive technology and to learn first-hand more about the present advances and in the field. To launch as soon as possible, PHI's Chief Scientific Officer, Kersti Alm, will kick-start the office now mid-November.